secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENZO BIOCHEM INC (—)
CIK:        0000316253
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001213900-23-074469
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Hamid Erfanian resigns; COO Kara Cannon named Interim CEO
-------------------------------------------------------------

- CEO Hamid Erfanian resigned effective Sep 5, 2023; final employment date Nov 18, 2023.
- Severance: $624k base (12 months), $187.2k bonus, $1.5M restricted stock grant, accelerated RSUs & options.
- COO Kara Cannon appointed Interim CEO; base salary increased from $308k to $350k.
- Company shifts focus to life sciences division after divestiture of Enzo Clinical Lab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/316253/000121390023074469/0001213900-23-074469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/316253/000121390023074469/ea184646-8k_enzobio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-074469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer